DALLAS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AMN Healthcare, the leader and innovator in total talent solutions including healthcare workforce technology, today announced the launch of ShiftWise Flex, a next-generation vendor management system (VMS) that leverages state-of-the-art features and automation to empower healthcare organizations with the ability to create a financially sustainable and agile workforce to deliver on their healthcare mission.
As the first healthcare-focused VMS to enter the market in 2002, ShiftWise is the trusted industry leading staffing technology used by many of the nation’s largest and most robust healthcare systems. ShiftWise Flex, AMN Healthcare’s next- generation enhanced product, is the only vendor neutral platform that automates and streamlines the contingent labor management process for nursing, allied health, locums and non-clinical professionals. The platform gives healthcare systems unprecedented flexibility and control over their workforce and ability to meet patient demand.
“We have been working tirelessly to push the boundaries of innovation, and today, we unveil a new era of healthcare workforce technology. With ShiftWise Flex, we have combined our longstanding proven technology with cutting-edge developments and reimagined configuration agility. Healthcare organizations can expect to optimize labor costs, access more talent and build an agile workforce to deliver incredible patient outcomes,” said Nishan Sivathasan, Division President of Workforce Technology at AMN Healthcare.
Key capabilities of ShiftWise Flex include:
For more information about ShiftWise Flex, please visit https://www.amnhealthcare.com/campaign/tech/shiftwise-flex/.
About AMN Healthcare
AMN Healthcare is the leader and innovator in total talent solutions for healthcare organizations across the United States. The Company provides access to the most comprehensive network of quality healthcare professionals through its innovative recruitment strategies and breadth of career opportunities. With insights and expertise, AMN Healthcare helps providers optimize their workforce to successfully reduce complexity, increase efficiency and improve patient outcomes. AMN total talent solutions include managed services programs, clinical and interim healthcare leaders, temporary staffing, permanent placement, executive search solutions, vendor management systems, recruitment process outsourcing, predictive modeling, language interpretation services, revenue cycle solutions, and other services. Clients include acute-care hospitals, community health centers and clinics, physician practice groups, retail and urgent care centers, home health facilities, schools, and many other healthcare settings. AMN Healthcare is committed to fostering and maintaining a diverse team that reflects the communities we serve. Our commitment to the inclusion of many different backgrounds, experiences and perspectives enables our innovation and leadership in the healthcare services industry. For more information about AMN Healthcare, visit www.amnhealthcare.com.
Media Contact Corporate Communications AMN Healthcare This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Contact Randle Reece Senior Director, Investor Relations & Strategy AMN Healthcare (866) 861-3229 This email address is being protected from spambots. You need JavaScript enabled to view it. |
Last Trade: | US$24.46 |
Daily Change: | 0.54 2.26 |
Daily Volume: | 15,443 |
Market Cap: | US$931.190M |
November 07, 2024 August 27, 2024 August 08, 2024 July 09, 2024 May 09, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB